Avidity Biosciences Inc
RNAM
Rang în acțiuni
#2068
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Preț acțiune
$71.34
Ultima sincronizare: 2026-03-03
Capitalizare de piață
$9.84B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
-
Țară
US
Tranzacționează Avidity Biosciences Inc (RNAM)
Categorie
Healthcare
Raport P/B pentru Avidity Biosciences Inc (RNAM)
Raport P/B la data de October 2026 TTM: 6.44
Conform celor mai recente rapoarte financiare și prețului acțiunilor Avidity Biosciences Inc, raportul P/B actual (TTM) este 6.44. La sfârșitul anului 2024, compania avea un P/B de 5.69.
Istoricul raportului P/B pentru Avidity Biosciences Inc din 2018 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 6.44 | 8.80% |
| 2025 | 5.92 | 4.15% |
| 2024 | 5.69 | -46.29% |
| 2023 | 10.59 | 61.58% |
| 2022 | 6.55 | -16.92% |
| 2021 | 7.89 | 53.53% |
| 2020 | 5.14 | -112.32% |
| 2019 | -41.71 | -37.04% |
| 2018 | -66.25 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | -2.95% |
US
|
|
| 13.6307 | 111.63% |
US
|
|
| 4.4521 | -30.88% |
AU
|
|
| 3.2932 | -48.87% |
BE
|
|
| 6.3632 | -1.21% |
NL
|
